Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$4.77
-4.3%
$4.42
$3.20
$28.60
$46.66M0.27425,994 shs374,025 shs
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$0.64
+1.2%
$0.76
$0.45
$1.99
$48.07M1.51219,897 shs73,257 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$0.87
-0.5%
$0.81
$0.61
$6.80
$48.89M1.3275,004 shs25,721 shs
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$0.67
+5.0%
$0.67
$0.48
$3.55
$12.02M0.861.32 million shs68,431 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-0.40%+0.20%+18.85%+31.05%-73.51%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-4.92%+4.87%-20.20%-49.15%-61.08%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
+8.80%-4.82%-1.87%+16.78%-76.55%
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-5.57%-18.31%-16.57%-15.78%-60.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bluebird bio, Inc. stock logo
BLUE
bluebird bio
3.0737 of 5 stars
3.15.00.00.02.31.71.3
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
4.2078 of 5 stars
3.52.00.04.73.30.81.3
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.523 of 5 stars
3.24.00.00.03.05.00.6
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
1.0589 of 5 stars
0.05.00.00.01.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$44.60835.99% Upside
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.00
Buy$3.00370.22% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.33
Hold$4.00361.89% Upside
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TRIB, PRLD, CUE, and BLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/29/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.00
4/8/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/31/2025
bluebird bio, Inc. stock logo
BLUE
bluebird bio
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$103.95M0.45N/AN/A$35.59 per share0.13
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$7.99M6.02N/AN/A$0.82 per share0.78
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M6.98N/AN/A$4.32 per share0.20
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$61.56M0.20N/AN/A($3.14) per share-0.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/A
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$50.73M-$0.67N/AN/AN/A-468.02%-156.38%-88.07%8/13/2025 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%8/11/2025 (Estimated)
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-$24.02M-$2.82N/AN/AN/A-34.39%N/A-21.37%5/29/2025 (Estimated)

Latest TRIB, PRLD, CUE, and BLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2024
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-$0.28-$1.14-$0.86-$0.76$16.50 million$15.86 million
5/12/2025Q1 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million
5/6/2025Q1 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.47-$0.42+$0.05-$0.42N/AN/A
3/28/2025Q4 2024
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million
3/10/2025Q4 2024
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.49-$0.38+$0.11-$0.38N/A$4.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$0.2233.03%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
0.05
2.22
2.22
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
7.04
7.04
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
N/A
1.64
0.87

Institutional Ownership

CompanyInstitutional Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
78.97%

Insider Ownership

CompanyInsider Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.40%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
10.78%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.79 million9.59 millionOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
6075.35 million55.58 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.46 million20.47 millionOptionable
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
48018.05 million16.57 millionOptionable

Recent News About These Companies

Trinity Biotech receives non-compliance notice from Nasdaq
Trinity Biotech zeroes in on CGM
Trinity Biotech announces additional funding for transformation plan

New MarketBeat Followers Over Time

Media Sentiment Over Time

bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$4.76 -0.22 (-4.32%)
As of 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$0.64 +0.01 (+1.19%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$0.87 0.00 (-0.46%)
As of 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Trinity Biotech stock logo

Trinity Biotech NASDAQ:TRIB

$0.67 +0.03 (+5.03%)
As of 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.